GSK Buying Corixa: $300M Brings MPL Facility, More
Vaccine partner GlaxoSmithKline plc plans to buy Corixa Corp. for $300 million in cash, paying $4.40 per share - a 48 percent premium to the closing price on April 28, the day before the deal was made public. (BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.